Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.51 |
| ▸ | DHODH | Q02127 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491855 | 0.88 | F10 (0.46) | F10DHODHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6501038 | 0.83 | F10 (0.49) | F10 | |
| SCHEMBL6501822 | 0.82 | F10 (0.51) | F10DHODHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8357787 | 0.81 | F10 (0.57) | F10 | |
| SCHEMBL6493858 | 0.77 | DHODH (0.51) | F10DHODHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6492465 | 0.76 | F10 (0.51) | F10 | |
| SCHEMBL6503753 | 0.75 | DHODH (0.52) | F10DHODHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6496301 | 0.73 | F10 (0.60) | F10 | |
| SCHEMBL8357269 | 0.71 | F10 (0.55) | F10 | |
| SCHEMBL5645113 | 0.70 | RPA1 (0.48) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885DHODH 3234/4885CYP1A2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.